Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients

NCT04243122 is registered in ClinicalTrials.gov with Ottawa Hospital Research Institute as lead sponsor.

NCT NCT04243122
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04243122 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Pilot Randomized Controlled Trial Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Lead sponsor
Ottawa Hospital Research Institute
Phase
Phase 2
Overall status
Completed
Start date
February 17, 2021
Completion date
May 3, 2024
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

essential thrombocythemia (et), jak2 mutation, myeloproliferative neoplasm (mpn), polycythemia vera (pv), primary myelofibrosis, venous thromboembolism (vte)